Drugs

Iodine Products Inc

FDA issued a warning letter to Iodine Products Inc (So. Miami, FL, United States) on Mar 25, 2022. Subject: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19).

From the letter: “your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19*1* in people.”

So. Miami, FL, United StatesIssued Mar 25, 2022Posted Mar 28, 2022No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
4 findings · 1 issue type
Cited
No CFR or ISO section
Response due
Not stated in the letter
FDA asks for
3 actions
Named as possible actions
Seizure, injunction, refusal of admission
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01OtherProducts are unapproved new drugs and misbranded drugs because they are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 without FDA approval.
your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19*1* in people.
02OtherThe products are unapproved new drugs and misbranded drugs under the FD&C Act.
these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352.
03OtherIntroduction of these products into interstate commerce is prohibited.
The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).
04OtherAdvertising COVID-19 prevention or treatment claims without competent and reliable scientific evidence violates the FTC Act.
it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence.

What FDA requested

  • Send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps taken to address the violations, including an explanation of each step taken to prevent recurrence and copies of related documentation
  • If unable to take action completely within 48 hours, state the reason for the delay and the time within which you will do so
  • If you believe your products are not in violation, include your reasoning and supporting information

FDA Warning Letter

27 paragraphs · 2 sections

Text as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

1WARNING LETTER

0 paragraphs

2RE: CMS# 628296

17 paragraphs

Date: March 25, 2022

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https://www.iodineproducts.com on March 2, 2022, and March 23, 2022, respectively. We also reviewed your social media websites at https://www.youtube.com/c/IodineProducts/videos, https://www.facebook.com/IodineProducts, and https://www.instagram.com/iodineproducts/?hl=en, where you direct consumers to your website, http://www.iodineproducts.com/, to purchase your products. The FDA has observed that your website offers Liquid Mask Spray Anti-Viral and The COVID-Killer for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).

There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.

Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19 include:

“Our new Anti-Viral Liquid Mask is a COVID KILLER. Once you use it, you’re protected. Doctors use it to prevent the transmission of COVID-19 between doctors, staff and patients worldwide. It works! . . . In your mouth. Spray 2-3 times in your mouth. Breathe inwards to pull the iodine aerosol into your throat . . . In your nose . . . make sure to get 1-2 sprays directly into your nose. Sniff to pull it upward.” [from your webpage https://www.iodineproducts.com/product/liquid-mask-sprayanti-viral-large/]

“Lab and clinical studies show it kills ALL viruses, including the COVID-19 coronavirus, on contact in 15-30 seconds . . . A recent clinical study proves that the active ingredients in our 10 ml Liquid Mask CURE COVID-19 patients and simultaneously PREVENT transmission as they kill COVID-19 virus particles . . . Tags: anti-viral, COVID, COVID-19, Cure” [from your webpage https://www.iodineproducts.com/product/liquid-mask-spray-anti-viral-large/]

“The COVID-Killer 10 Ml Liquid Mask Anti-Viral Spray . . . Our 10-day 10 ml Liquid Mask is a COVID-19 virus killer. It sprays easily into nose and throat where it forms a protective coating that will last. Moreover, if you do come in to contact with a virus, such as . . . COVID . . . the iodine in the mask spray will kill is [sic] on contact within seconds . . . There are more studies that show that iodine kills COVID-19.” [from your webpage https://www.iodineproducts.com/product/10-ml-liquidmask-anti-viral-nose-throat-spray-small/]

“Liquid Mask – only at iodineproducts.com – to Prevent COVID transmission . . . To truly prevent the transmission of this disease organism (the SARS-CoV-2 virus), you need Liquid Mask.” [from a January 8, 2021 post on your YouTube webpage https://www.youtube.com/c/IodineProducts/videos]

“Our new free LIQUID MASK is a viral killer . . . This product in various forms is being used . . . to prevent the transmission of COVID-19 . . . PREVENT COVID! . . . Use our FREE Covid Killing Liquid Mask . . .” [from a January 11, 2021 post on your Facebook webpage https://www.facebook.com/IodineProducts]

“#11 of 19 Ways to Avoid Covid-19 . . . Tip #11 Get Liquid Mask . . . Liquid Mask kills the virus . . . #covid #covid_19 . . . #tipsforcovid19 #Covidtips #Covidfree . . . #covidrelief #covidliquidmasks” [from a February 28, 2021 post on your Instagram webpage https://www.instagram.com/p/CL1eUlCHIeM/]

You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.

This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.

Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov

FTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.

Sincerely, /S/

Donald D. Ashley Director Office of Compliance Center for Drug Evaluation and Research Food and Drug Administration

Sincerely, /S/

Serena Viswanathan Associate Director Division of Advertising Practices Federal Trade Commission

_____________________________

1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).

2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx.

3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https://trumpwhitehouse.archives.gov/presidential-actions/proclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak/.

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

This letter cites no 21 CFR section or ISO 13485 clause.

Issue types

OtherAI-assigned issue type140letters4findings here
25 letters issued this year vs 30 by the same date last year · -17%

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
So. Miami, FL, United States
Letter posted date
Mar 28, 2022
Letter issue date
Mar 25, 2022
Addressed to
Not recorded
Inspection dates · model-assisted
Mar 2, 2022 to Mar 23, 2022
Response window
Not verified in this snapshot. Consult the original letter.
Record length
1,585 words · 0 recorded redactions
Published status
No published close-out
FDA reference
628296
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.